ClinicalTrials.gg
Active, not recruitingNCT04877691Tulip SCUpdated Jul 27, 2026

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

A Phase 3 interventional study of Medi-546 and Placebo in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Active, not recruiting at 140 sites in 15 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
6th of 20
367 · median 159
Started
2021
with 3 others
Phase 3
9 of 20
4 open now
Primary completion
2025-08
later than 0 of 10 live
Registered
9th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 9 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 9th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

Read the detailed description

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of a subcutaneous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral glucocorticoids, antimalarial, and/or immunosuppressants. The study will be performed in adult participants of 18 to 70 years of age.

Approximately 360 participants receiving SOC treatment will be randomised in a 1:1 ratio to receive a fixed subcutaneous dose of anifrolumab or placebo administered once weekly via an accessorized prefilled syringe and with the primary endpoint evaluated at Week 52. Subjects who complete Week 52 may enter into open-label extension (OLE). All patients who enter the OLE Period will receive a fixed subcutaneous dose of anifrolumab for up to 52 weeks. Study intervention will be administered SC via an accessorised prefilled syringe (aPFS).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosuss Anifrolumab, Adult patients, BICLA, glucocorticoids, Immunosuppressant(s), sub-cutaneous
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have a diagnosis of pediatric or adult SLE according to the ACR 1997 revised criteria for ≥ 24 weeks prior to signing the ICF
  2. To be eligible a patient must have SLEDAI-2K ≥ 6 points and "Clinical" SLEDAI-2K score ≥4 points at screening
  3. BILAG2004 with at least 1 of the following:

    1. BILAG2004 level A disease in ≥ 1 organ system
    2. BILAG2004 level B disease in ≥ 2 organ systems
  4. Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 VAS at Screening
  5. Antinuclear antibody, and/or Anti-dsDNA and/oranti-Smith positive at Screening,
  6. Must be on stable background standard therapy with DMARD, or anti-malarials alone or in combinations.

Exclusion criteria

Exclusion Criteria:

  1. Active severe or unstable neuropsychiatric SLE
  2. Active severe SLE-driven renal disease
  3. History of any non-SLE disease that has required treatment with oral or parenteral for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF.
  4. History of recurrent infection requiring hospitalization and IV antibiotics (eg, 3 or more of the same type of infection over the previous 52 weeks).
  5. Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the patient to infection, or a positive result for (HIV) infection confirmed by central laboratory at Screening.
  6. At Screening, confirmed positive test for serology and positive test for antibody
  7. Any severe case herpes zoster infection at any time prior to Week 0 (Day 1),
  8. Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization.
  9. History of cancer, apart from:

    1. Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy ≥ 3 months prior to Week 0 (Day 1)
    2. Cervical cancer in situ treated with apparent success with curative therapy ≥ 1 year prior to Week 0 (Day 1).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    Solution for injection in aPFS

    Drug: Medi-546

  • Placebo comparator
    Placebo

    Solution for injection in aPFS

    Drug: Placebo

Interventions

  • Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.

  • DrugPlacebo

    Solution for injection in aPFS

06

What researchers measure

Primary outcomes

  1. British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response

    BICLA response is a composite binary endpoint whereby responders are defined by meeting all of the following criteria: * Improvement from baseline in disease activity as measured by BILAG-2004. Improvement is defined as a reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥ 1 new BILAG-2004 A or ≥ 2 new BILAG 2004 B. * No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of \> 0 points in SLEDAI-2K. * No worsening from baseline in the patient's lupus disease activity, where worsening is defined as an increase ≥ 0.30 points on a 3-point PGA VAS.

    Time frame: At week 52

Secondary outcomes

  1. Time to first BICLA response sustained through Week 52

    Time from first dose to first BICLA response that is consecutively maintained through Week 52

    Time frame: Baseline through to Week 52

  2. BICLA response with maintained low (or reduced) use of oral corticosteroid (OCS)

    Response is defined by being a BICLA responder at Week 52 and having maintained low (or reduced) OCS use through Week 52. Maintained OCS use is defined as follows: * If baseline OCS ≥ 10 mg/day an OCS dose of ≤ 7.5 mg/day prednisone or equivalent must be achieved by Week 40 and an OCS dose ≤ 7.5 mg/day prednisone or equivalent must be maintained from Week 40 to Week 52. * If baseline OCS \< 10 mg/day, OCS dose at Week 40 must be less than or equal to OCS dose at baseline, with no increase from Week 40 OCS dose between Week 40 and Week 52.

    Time frame: At week 52

  3. Time to flare

    Flare defined as either 1 or more BILAG 2004 A or 2 or more BILAG 2004 B compared to previous visit

    Time frame: Baseline through to Week 52

  4. Maintained oral corticosteroid (OCS) reduction among patients with baseline OCS ≥10 mg/day.

    Achieving maintained OCS reduction through Week 52 is defined by meeting all of the following criteria: * Achieve an OCS dose of ≤ 7.5 mg/day prednisone or equivalent by Week 40 * Maintain an OCS dose ≤ 7.5 mg/day prednisone or equivalent from Week 40 to Week 52 * No discontinuation of investigational product * No use of restricted medications beyond the protocol allowed threshold before assessment

    Time frame: At week 52

  5. Annualized flare rate

    Flare defined as either 1 or more BILAG 2004 or 2 or more BILAG2004 B compared to previous visit

    Time frame: Baseline through to Week 52

  6. SRI4

    Proportion of patients achieving a SRI of ≥ 4 (SRI\[4\]) response at Week 52, defined by meeting all of the following criteria: Reduction from baseline of ≥ 4 points in the SLEDAI-2K No new organ systems affected as defined by 1 or more BILAG-2004 A or 2 or more BILAG 2004 B items compared to baseline using BILAG-2004 No worsening from baseline in the patients' lupus disease activity, where worsening is defined by an increase ≥ 0.30 points on a 3-point PGA VAS.

    Time frame: At week 52

Other outcomes

  1. Adverse Event Overview

    Overview of AEs, SAEs and AESIs

    Time frame: Up to 2 years 4 months

07

Study locations

140 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Paradise Valley, Arizona 85253, United States
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    El Cajon, California 92020, United States
  • Research Site
    Fullerton, California 92835, United States
  • Research Site
    Hemet, California 92543, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Menifee, California 92586, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Clearwater, Florida 33759, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Miami, Florida 33180, United States
  • Research Site
    Tampa, Florida 33613, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Lansing, Michigan 48911, United States
  • Research Site
    Newark, New Jersey 07103, United States
  • Research Site
    Las Cruces, New Mexico 88011, United States
  • Research Site
    Brooklyn, New York 11201, United States
  • Research Site
    Manhasset, New York 11030, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Potsdam, New York 13676, United States
  • Research Site
    Charlotte, North Carolina 28203, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15224, United States
  • Research Site
    Reading, Pennsylvania 19610, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Grapevine, Texas 76051, United States
  • Research Site
    Ciudad de Buenos Aires, C1431FWO, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Pergamino, B2700CPM, Argentina
  • Research Site
    Quilmes, B1878GEG, Argentina
  • Research Site
    Rosario, S2000PBJ, Argentina
  • Research Site
    Salta, A4400ANW, Argentina
  • Research Site
    San Isidro, 1643, Argentina
  • Research Site
    San Juan, 5400, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    San Miguel de Tucumán, T4000AXL, Argentina
  • Research Site
    San Miguel de Tucumán, T4000ICL, Argentina
  • Research Site
    Kardzhali, 6600, Bulgaria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Sevlievo, 5400, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Sofia, 1797, Bulgaria
  • Research Site
    Osorno, 5290000, Chile
  • Research Site
    Santiago, 7500010, Chile
  • Research Site
    Santiago, 7500571, Chile
  • Research Site
    Santiago, 7500588, Chile
  • Research Site
    Santiago, 7500710, Chile
  • Research Site
    Santiago, 7501126, Chile
  • Research Site
    Santiago, 8320000, Chile
  • Research Site
    Valdivia, 5090000, Chile
  • Research Site
    Barranquilla, 080002, Colombia
  • Research Site
    Barranquilla, 080020, Colombia
  • Research Site
    Bogotá, 110221, Colombia
  • Research Site
    Bucaramanga, 680003, Colombia
  • Research Site
    Chía, 250001, Colombia
  • Research Site
    Montería, 230002, Colombia
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Budapest, 1027, Hungary
  • Research Site
    Budapest, 1097, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Veszprém, 8200, Hungary
  • Research Site
    Chiba, 260-8712, Japan
  • Research Site
    Chūōku, 104-8560, Japan
  • Research Site
    Hamamatsu, 431-3192, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Itabashi-ku, 173-8610, Japan
  • Research Site
    Kita-gun, 761-0793, Japan
  • Research Site
    Kitakyushu-shi, 807-8555, Japan
  • Research Site
    Meguro-ku, 152-8902, Japan
  • Research Site
    Meguro-ku, 153-8515, Japan
  • Research Site
    Nagasaki, 852-8501, Japan
  • Research Site
    Nagoya, 457-8510, Japan
  • Research Site
    Nagoya, 460-0001, Japan
  • Research Site
    Okayama, 700-8607, Japan
  • Research Site
    Sagamihara-shi, 252-0375, Japan
  • Research Site
    Sasebo-shi, 857-1195, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Chihuahua City, 31000, Mexico
  • Research Site
    Culiacán, 80000, Mexico
  • Research Site
    Durango, 43080, Mexico
  • Research Site
    Guadalajara, 44130, Mexico
  • Research Site
    Guadalajara, 44650, Mexico
  • Research Site
    Guadalajara, 44950, Mexico

Showing the first 100 of 140 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Aug 2025, 50 months.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 50 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 7, 2021
StartActual
Jun 8, 2021
Primary completionActual
Aug 22, 2025
CompletionEst.
Nov 6, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04877691
Lead sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
May 7, 2021
Start date
Jun 8, 2021
Primary completion
Aug 22, 2025
Completion
Nov 6, 2026 (estimated)
Last update
Jul 27, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion